Systemic psoriasis medications: As per product label
No systemic medications: Participants not exposed to any systemic medications
Study summary
This observational study aims to assess pregnancy and infant outcomes among pregnant women with psoriasis who have been exposed to deucravacitinib treatment in the USA.
Eligibility
Sex
FEMALE
Min age
15 Years
Max age
50 Years
Healthy volunteers
No
Inclusion Criteria:
* Maternal age 15 through 50 years at date of conception
* Start of pregnancy, defined as the estimated date of conception, during the accrual period (09-Sep-2022 through 31-Oct-2026)
* Continuous medical and pharmacy coverage for a minimum of 6 months prior to and including the estimated date of conception
* Presence of psoriasis from 12 months prior to the date of conception through the end of pregnancy
Exclusion Criteria:
• Exposure to any known teratogens from 5 half-lives prior to the estimated date of conception through the end of the relevant exposure window
Primary outcome measure(s)
Number of infants born with Major Congenital Malformations (MCMs) — Up to 12 months after birth or date of health plan disenrollment MCMs defined as a structural abnormality with surgical, medical, or cosmetic importance (excluding chromosomal abnormalities or physiological features due to complications of prematurity, such as cryptorchidism, inguinal hernia, or isolated patent ductus arteriosus in infants born less than 37 weeks of gestation)
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.